NCT07165652View on ClinicalTrials.gov

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Male Adult Volunteers
Interventions
DRUG

NKF-INS(L)

Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.

DRUG

US-Humalog®

Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.

DRUG

EU-Humalog®

Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.

All Listed Sponsors
lead

Xentria, Inc.

INDUSTRY